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1. Introduction 
During a meal, two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP), are released from the small intestine into the 
vasculature and augment glucose-induced insulin secretion from the islet β-cells [1]. It has 
been estimated that 50-60% of the total insulin secreted during a meal results from the incretin 
response, mainly the combined effects of GIP and GLP-1 [2]. Previous studies have shown 
both GIP and GLP-1 stimulate β-cell proliferation, differentiation, and prevent apoptosis [3-6]. 
GLP-1 also has some actions such as inhibition of glucagon secretion and food intake, glucose 
homeostasis and slowing the gastric emptying [7-9]. However, GLP-1 has a short half-life of 1-
2 min following secretion in response to the nutrients ingestion because of its inactivation by 
dipeptidyl peptidase-IV (DPP-IV) [10], resulting in loss of insulinotropic activities. 
DPP-IV (CD26; E.C. 3.4.14.5) is a 110-kDa plasma membrane glycoprotein ectopeptidase that 
belongs to the prolyl oligopeptidase family [11]. It acts as a cleaving enzyme with the 
specificity for removing X-Pro or X-Ala dipeptides from the N terminus of polypeptides and 
proteins. It has a strong preference for Pro > Ala > Ser as the penultimate amino acid residue 
[10-12]. This enzyme is also capable of cleavage of N-terminal dipeptides with 
hydroxyproline (Hyp), dehydroproline, Gly, Val, Thr or Leu [10-14]. GLP-1 has Ala as the 
N-terminal penultimate amino acid residue, and therefore it is the substrate of DPP-IV. This 
finding that over 95% of the degradation of GLP-1 is attributed to the action of DPP-IV led 
to an elevated interest in inhibition of this enzyme for the treatment of type 2 diabetes [15]. 
Some previous studies have shown that specific DPP-IV inhibition increased the half-life of 
total circulating GLP-1, decreased plasma glucose, and improved impaired glucose 
tolerance in animal and human experiments [16-18]. 
There are several chemical compounds used in vitro and in animal models to inhibit DPP-IV 
activity, such as Val-pyrrolidide [17], NVP-DPP728 [18], Lys[Z(NO2)]-thiazolidide and 
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Lys[Z(NO2)]-pyrrolidide [19]. However, such chemical compounds, which often have to be 
administered by injection, may result in side effects as chemical drugs often do. Thus, to 
develop safe and natural DPP-IV inhibitors as the therapeutic agents of type 2 diabetes is 
necessary. 
Proteins are well known as precursors of bioactive peptides. In recent years, peptides have 
been identified to possess physiological functions, such as immunomodulatory [20], 
antimicrobial [21], antihypertensive [22], anticancer [23], antioxidative [24] and cholesterol-
lowering activities [25]. These bioactive peptides are mostly derived from milk, wheat, 
soybean, egg and fish proteins by enzymatic hydrolysis or fermentation [26]. Food protein 
hydrolysates are well-used and natural food ingredients, and therefore they are believed to 
be safe for consumers when they are served as functional foods. Some studies have reported 
that bioactive peptides possessed DPP-IV inhibitory activity. Diprotins A and B, isolated 
from culture filtrates of Bacillus cereus BMF673-RF1, are bioactive peptides found to exhibit 
the DPP-IV inhibitory activity with IC50 values of 1.1 and 5.5 μg/mL; they were elucidated to 
be Ile-Pro-Ile and Val-Pro-Leu, respectively [27]. Two bioactive peptides, Ile-Pro-Ala and 
Val-Ala-Gly-Thr-Trp-Tyr, derived from β-lactoglobulin hydrolysed by proteinase K and 
trypsin, showed IC50 values of 49 and 174 μM, respectively, against DPP-IV in vitro [28,29]. 
Two patents, WO 2006/068480 and WO 2009/128713 have shown that peptides derived from 
casein and lysozyme hydrolysates, respectively display DPP-IV inhibitory activity, and the 
peptides show in particular the presence of at least one Pro within the sequence and mostly 
as the penultimate N-terminal residue [30,31]. 
It is well-known that the dominant amino acid in gelatin is Gly, while the imino acids (Pro 
and Hyp) come second in abundance [32]. The amino acid composition of gelatin is 
characterized by a repeating sequence of Gly-X-Y triplets, where X is mostly Pro and Y is 
mostly Hyp. Inside gelatin molecule, Gly constitutes approximately 27% of the total amino 
acid pool [33]. The total amount of the imino acids is higher in mammalian (20-24%) than in 
fish (16-20%). In our previous study, we successfully isolated two peptides, Gly-Pro-Ala-Glu 
and Gly-Pro-Gly-Ala from Atlantic salmon skin gelatin, that showed dose-dependent 
inhibitory effects on DPP-IV with IC50 values of 49.6 and 41.9 μM, respectively [34]. 
According to the report of previous studies, DPP-IV inhibitory peptides consisted of at least 
one Pro and mostly as the penultimate N-terminal residue [32]. Therefore, the aim of this 
study was to examine the DPP-IV inhibitory activity of peptides derived from porcine skin 
gelatin, which constitutes higher content of imino acids than skin gelatin of Atlantic salmon, 
a kind of cold-water fish. This is expected to give insight into the possible utilization of 
porcine skin as a potential source of DPP-IV inhibitors that may be used in the treatment of 
type 2 diabetes to lower the risk of side effects. 
2. Materials and methods 
2.1. Materials and reagents 
Porcine skin gelatin (G-2500) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Alcalase® 2.4 L FG (from Bacillus licheniformis, 2.4 AU/g) (ALA) was the product from Novo-
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zymes North America Inc. (Salem, NC, Canada). DPP-IV (D7052, from porcine kidney), Gly-
Pro-p-nitroanilide hydrochloride, trichloroacetic acid (TCA), L-Leu and Diprotin A were 
purchased from Sigma-Aldrich. Trinitrobenzenesulfonic acid (TNBS) was from Fluka 
Biochemika (Oakville, ON, Canada). Other chemicals and reagents used were analytical 
grade and commercially available. 
2.2. Enzymatic hydrolysis 
One gram of the gelatin added with 50 mL ddH2O was incubated at 50°C for 10 min prior to 
the enzymatic hydrolysis. ALA in liquid form were weighed 10, 30, 50 mg and mixed with 1 
mL ddH2O. The hydrolysis reaction was started by the addition of enzymes at various 
enzyme/substrate ratios (E/S: 1%, 3%, and 5%). The reaction with ALA was conducted at pH 
8.0, respectively, and 50°C for up to 6 h. After hydrolysis, the hydrolysates were heated in 
boiling water for 15 min to inactivate enzymes and then cooled in cold water at room 
temperature for 20 min. Hydrolysates were adjusted their pH to 7.0 with 1 M NaOH and 
centrifuged (Du Pont Sorvall Centrifuge RC 5B, Mandel Scientific Co. Ltd, Guelph, ON, 
Canada) at 12,000g and room temperature for 15 min. The supernatant was lyophilized and 
stored at -25°C . 
2.3. Measurement of degree of hydrolysis 
Immediately prior to termination of hydrolysis, 4 mL of the hydrolysate were mixed with an 
equal volume of 24% TCA solution and centrifuged at 12200g for 5 min. The supernatant 
(0.2 mL) was added to 2.0 mL of 0.05 M sodium tetraborate buffer (pH 9.2) and 1 mL of 4.0 
mM TNBS and incubated at room temperature for 30 min in the dark. Then the mixture was 
added with 1.0 mL of 2.0 M NaH2PO4 containing 18 mM Na2SO3, and the absorbance was 
measured at 420 nm using a spectrophotometer (Cary 50 Bio UV-vis spectrophotometer, 
Varian, Inc., Santa Clara, CA, USA) [35,36]. Degree of hydrolysis (DH) was calculated as % 
DH=(h/htot) × 100, where DH=percent ratio of the number of peptide bonds broken (h) to the 
total number bonds per unit weight (htot) and htot=11.1 mequiv/g of gelatin [35]. L-Leu was 
used for drawing a standard curve. 
2.4. Determination of DPP-IV inhibitory activity 
DPP-IV activity determination in this study was performed in 96-well microplates 
measuring the increase in absorbance at 405 nm using Gly-Pro-p-nitroanilide as DPP-IV 
substrate [37]. The lyophilized hydrolysates were dissolved in 100 mM Tris buffer (pH 8.0) 
to the concentration of 10 mg/mL and then serially diluted. The hydrolysates (25 μL) were 
added with 25 μL of 1.59 mM Gly-Pro-p-nitroanilide (in 100 mM Tris buffer, pH 8.0). The 
mixture was incubated at 37°C °C for 10 min, followed by the addition of 50 μL of DPP-IV 
(diluted with the same Tris buffer to 0.01 Unit/mL). The reaction mixture was incubated at 
37°C for 60 min, and the reaction was stopped by adding 100 μL of 1 M sodium acetate 
buffer (pH 4.0). The absorbance of the resulting solution was measured at 405 nm with a 
microplate reader (iEMS reader MF; Labsystems, Helsinki, Finland). Under the conditions of 
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the assay, IC50 values were determined by assaying appropriately diluted samples and 
plotting the DPP-IV inhibition rate as a function of the hydrolysate concentration. 
2.5. Ultrafiltration 
Hydrolysates were fractionated by ultrafiltration (UF; Model ABL085, Lian Sheng Tech. Co., 
Taichung, Taiwan) with spiral wound membranes having molecular mass cutoffs of 2.5 and 
1 kDa. The fractions were collected as follows: >2.5 kDa, peptides retained without passing 
through 2.5 kDa membrane; 1-2.5 kDa, peptides permeating through the 2.5 kDa membrane 
but not the 1 kDa membrane; <1 kDa, peptides permeating through the 1 kDa membrane. 
All collected fractions were lyophilized and stored in a desiccator until use. 
2.6. High Performance Liquid Chromatography (HPLC) 
The fractionated hydrolysates by ultrafiltration exhibiting DPP-IV inhibitory activity were 
further purified using high performance liquid chromatography (Model L-2130 HPLC, 
Hitachi Ltd., Katsuda, Japan). The lyophilized hydrolysate fraction (100 μg) by gel filtration 
was dissolved in 1 mL of 0.1% trifluoroacetic acid (TFA) and 90 μL of the mixture, was then 
injected into a column (ZORBAX Eclipse Plus C18, 4.6 × 250 mm, Agilent Tech. Inc., CA, 
USA) using a linear gradient of acetonitrile (5 to 15% in 20 min) in 0.1% TFA under a flow 
rate of 0.7 mL/min. The peptides were detected at 215 nm. Each collected fraction was 
lyophilized and stored in a desiccator until use. 
2.7. Identification of amino acid sequence 
An accurate molecular mass and amino acid sequence of the purified peptides was 
determined using a Q-TOF mass spectrometer (Micromass, Altrincham, UK) coupled with 
an electrospray (ESI) source. The purified peptides were separately infused into the ESI 
source after being dissolved in methanol/water (1:1, v/v), and the molecular mass was 
determined by the doubly charged (M+2H)+2 state in the mass spectrum. Automated Edman 
sequencing was performed by standard procedures using a 477-A protein sequencer 
chromatogram (Applied Biosystems, Foster, CA, USA). 
2.8. Peptide synthesis 
Peptides were prepared by the conventional Fmoc solid-phase synthesis method with an 
automatic peptide synthesizer (Model CS 136, CS Bio Co. San Carlos, CA, USA), and their 
purity was verified by analytical RP-HPLC-MS/MS. 
2.9. Statistical analysis 
Each data represents the mean of three samples was subjected to analysis of variance 
(ANOVA) followed by Tukey‘s studentized range test, and the significance level of P＜0.05 
was employed. 
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3. Results and discussion 
3.1. Degree of hydrolysis 
The DH of porcine skin gelatin hydrolyzed with ALA increased dramatically during the 
initial 1 h, and then increased gradually thereafter (Fig. 1). Also the highest DH was 
obtained with the highest E/S ratio. The highest DH (%) for ALA was 16.7% and obtained at 
the E/S ratio of 5% and 6-h hydrolysis. 
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Figure 1. Degree of hydrolysis of porcine skin gelatin hydrolyzed with ALA at various E/S ratio. 
3.2. DPP-IV inhibitory activity of hydrolysates 
The DPP-IV inhibitory activity of porcine skin gelatin hydrolysates at the concentration of 10 
mg/mL was shown in Fig. 2. The gelatin sample without hydrolysis (0 h) showed 9.2% 
inhibitory rate on DPP-IV. The DPP-IV inhibitory activity of the gelatin hydrolysates 
increased with E/S ratio and hydrolysis time. The DPP-IV inhibition rates of the 1-h 
hydrolysates with the E/S ratio of 1, 3 and 5% were 27.2, 44.3 and 48.8%, respectively; while 
those of 6-h hydrolysates increased to 52.0, 59.7 and 60.0%. The hydrolysates with the E/S 
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ratio of 3% and 5%, and the hydrolysis time of 4 h and 6 h showed the highest DPP-IV 
inhibition rates between 57.4 to 60.0% among all the samples (P<0.05); in the meanwhile, the 
inhibition rates between the four samples were not significantly different (P>0.05). The 
results showed that the hydrolysates with the smaller size of peptides due to the higher DH 
possessed greater DPP-IV inhibitory activity. Patent WO 2006/068480 has demonstrated that 
the hydrolysates possessed great DPP-IV inhibitory activities referred to a mixture of 
peptides derived from hydrolysis of proteins with the percentage of hydrolysed peptide 
bonds of most preferably 20 to 40% [30]. As the economic concern for saving time and 
enzyme used, the hydrolysate with E/S ratio of 3% and 4-h hydrolysis was adopted for 
furher purification and analysis. 
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Figure 2. DPP-IV inhibitory rate of porcine skin gelatin hydrolysates. Different letters indicate the 
significant differences (P<0.05). 
3.3. DPP-IV inhibitory activtiy of hydrolysates fractionated by UF 
The DPP-IV inhibitory activity of hydrolysates with the E/S ratio of 3% and 4-h hydrolysis at 
the concentration of 1 mg/mL fractionated by UF was shown in Fig. 3A. The result showed 
the UF fractions of 1-2.5 kDa and < 1 kDa had insignificantly different (P>0.05) and higher 
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DPP-IV inhibition rates of 30.6% and 30.7%, respectively (P<0.05), than that within the > 2.5 
kDa fraction displaying an inhibition rate of 28.2%. < 1-kDa fraction was selected for further 
analysis on the basis of the small size peptides may pass through the digestive tract without 
degradation. The IC50 value of the < 1 kDa fraction was determined and found as 1.50 
mg/mL (Fig. 3B). The result in this study is in agreement with the former studies using 
various protein sources that reported the preferable DPP-IV inhibitory peptides derived 
from food protein consisted of 2-8 amino acid residues [30,31], and their molecular weights 
were supposed between 200 to 1000 Da. 
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Figure 3. (A) DPP-IV inhibition rate of porcine skin gelatin hydrolysate fractionated by UF at the 
concentration of 1 mg/mL. (B) DPP-IV inhibition rate of the < 1 kDa UF fraction at various 
concentrations. Different letters indicate the significant differences (P<0.05). 
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3.4. Purification of DPP-IV-inhibitory peptides by HPLC 
The elution profile and DPP-IV inhibitory activity of the peptide fractions from the < 1 kDa 
UF fraction separated by HPLC were shown in Fig. 4A and B. To obtain a sufficient  
amount of purified peptide, chromatographic separations were performed repeatedly. Five 
fractions (F-1 to F-5) were obtained upon HPLC separation of the < 1 kDa UF fraction (Fig. 
4A), and they were lyophilized and then used to determine their DPP-IV inhibitory activities 
at the concentration of 100 μg/mL. The result showed that the fraction F-3 had the highest 
DPP-IV inhibition rate of 64.6% (P<0.05), as compared to the others which showed the 
inhibition rates between 26.7 to 45.6%, and its IC50 value was also determined as 62.9 μg/mL 
(Fig. 4C). Therefore, the fraction F-3 was used to identify the amino acid sequences of the 
peptides. 
 
 
 
 
Figure 4. (A) Elution profile and (B) DPP-IV inhibition rate of the peptide fractions from the < 1 kDa UF 
fraction separated by HPLC. (C) DPP-IV inhibition rate of fraction F-3 at various concentrations. The 
DPP-IV inhibition rate was determined with each HPLC fraction at the concentration of 100 μg/mL. 
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3.5. Amino acid sequence of DPP-IV inhibitory peptides 
Two peptides were identified in fraction F-3, and their amino acid sequences were  
Gly-Pro-Hyp (285.3 Da) and Gly-Pro-Ala-Gly (300.4 Da). Patent WO 2006/068480 has 
reported that 21 peptides which were capable of inhibiting DPP-IV activity showed  
a hydrophobic character, had a length varying from 3-7 amino acid residues and in 
particular the presence of Pro residue within the sequence [30]. The Pro residue  
was located as the first, second, third or fourth N-terminal residue, but mostly as the 
second N-terminal residue. Besides, the Pro residue was flanked by Leu, Val, Phe, Ala 
and Gly. In the present study, both peptides comprised Pro as the second N-terminal 
residue, and the Pro residue was flanked by Ala and Gly. Moreover, the peptides were 
composed of mostly hydrophobic amino acid residues, such as Ala, Gly and Pro, and one 
peptide comprised a charged amino acid, Glu, as the C-terminal residue. The present 
results therefore are consistent with the hypothesis demonstrated in the previous study 
[30]. 
3.6. DPP-IV-inhibitory activity of the synthetic peptides 
The DPP-IV inhibitory activity of the two synthetic peptides and Diprotin A at various 
concentrations was determined (Fig. 5). The IC50 was calculated for each of the peptides. 
Diprotin A is well-known as the peptide with the greatest DPP-IV inhibitory activity, 
and its IC50 value was found as 24.7 μM in the present study (Fig. 4C). The IC50 values of 
the two synthetic peptides, Gly-Pro-Hyp and Gly-Pro-Ala-Gly, were 49.6 and 41.9 μM, 
respectively (Fig. 4A, B). In the previous study, the IC50 values against DPP-IV of 
Diprotin A and Diprotin B isolated from culture filtrates of B. cereus BMF673-RF1 were 
3.2 and 16.8 μM, respectively [27]. Moreover, Ile-Pro-Ala and Val-Ala-Gly-Thr-Trp-Tyr, 
both prepared from β-lactoglobulin showed IC50 values of 49 and 174 μM against DPP-
IV, respectively [28,29]. Patent WO 2006/068480 reported that Diprotin A showed the IC50 
value of about 5 μM against DPP-IV, and five peptides, His-Pro-Ile-Lys, Leu-Pro-Leu-
Pro, Leu-Pro-Val-Pro, Met-Pro-Leu-Trp and Gly-Pro-Phe-Pro, comprised 4 amino acids 
with Pro as the penultimate N-terminal residue displayed their IC50 values between 76 to 
120 μM [30]. The results showed that the two peptides obtained in this study showed 
lower DPP-IV inhibitory activity than only Diprotin A and B, which were composed with 
3 amino acid residues. However, they had similar inhibition effect to Ile-Pro-Ala but 
greater than other peptides comprised 4 or more amino acid residues. It is interesting 
that the ultimate N-terminal residues of the peptides mentioned above are all 
hydrophobic amino acids, and therefore we assumed that DPP-IV inhibitory activity of 
bioactive peptides may be determined by the amino acid length and the two N-terminal 
amino acid sequence of X-Pro, where X is the hydrophobic amino acid and preferably 
smaller in size. In conclusion, we found two peptides, Gly-Pro-Hyp and Gly-Pro-Ala-
Gly, isolated from porcine skin gelatin hydrolysates having the inhibitory activity 
against DPP-IV. 
 
Bioactive Food Peptides in Health and Disease 214 
 
 
Figure 5. DPP-IV inhibition rates and IC50 values of the synthetic peptides and diprotin A. 
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4. Conclusion 
This study has clearly demonstrated that porcine skin gelatin could be a good protein source 
to produce DPP-IV inhibitory peptides by hydrolysis with ALA. The two peptides identified 
in this study may have the potential for the therapy or prevention of type 2 diabetes. Further 
studies using in vitro simulated gastrointestinal digestion and Caco-2 cell permeate analysis 
and in vivo animal model systems are therefore necessary to ascertain the required standards 
of evidence for DPP-IV inhibitory potential of bioactive peptides derived from porcine skin 
gelatin. 
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